Pfizer Inc. (PFE)
NYSE: PFE · Real-Time Price · USD
25.78
+0.22 (0.86%)
At close: Jul 10, 2025, 4:00 PM
25.72
-0.06 (-0.23%)
Pre-market: Jul 11, 2025, 5:58 AM EDT
Pfizer Revenue
Pfizer had revenue of $13.72B in the quarter ending March 30, 2025, a decrease of -7.82%. This brings the company's revenue in the last twelve months to $62.46B, up 11.65% year-over-year. In the year 2024, Pfizer had annual revenue of $63.63B with 6.84% growth.
Revenue (ttm)
$62.46B
Revenue Growth
+11.65%
P/S Ratio
2.34
Revenue / Employee
n/a
Employees
n/a
Market Cap
146.57B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 63.63B | 4.07B | 6.84% |
Dec 31, 2023 | 59.55B | -41.62B | -41.14% |
Dec 31, 2022 | 101.18B | 19.89B | 24.46% |
Dec 31, 2021 | 81.29B | 39.64B | 95.16% |
Dec 31, 2020 | 41.65B | 746.00M | 1.82% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PFE News
- 21 hours ago - 3 To Watch Of 23 'Safer' July Dividends From 46 Fortune World's Most Admired Companies - Seeking Alpha
- 22 hours ago - Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win - Reuters
- 23 hours ago - XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence - Business Wire
- 2 days ago - Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others - CNBC
- 3 days ago - My Top 10 High-Yield Dividend Stocks For July 2025: One Yields 12%-Plus - Seeking Alpha
- 3 days ago - Forget Get Rich Quick: The Real Dividend Strategy That Built My Income Machine - Seeking Alpha
- 5 days ago - 5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 9% (July 2025) - Seeking Alpha
- 7 days ago - Pfizer: Options Activity Speaks Bullish - Seeking Alpha